We are live on ! Find out more
Superstring Capital Management

Superstring Capital Management Portfolio holdings

AUM $200M Turnover 47.73%
1-Year Est. Return 216.62%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+216.62%
3 Year Est. Return
+1,109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$84M
AUM Growth
-$31.4M
Cap. Flow
-$23M
Cap. Flow %
-27.39%
Top 10 Hldgs %
66.01%
Holding
53
New
14
Increased
7
Reduced
9
Closed
19
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.3 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.3 years

Sector Composition

Rank Sector Weight
1 Healthcare 99.75%
2 Miscellaneous 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ZLAB icon
1
Zai Lab
ZLAB
$2.74B
$10.7M 12.68%
294,947
-108,683
-27% -$3.34M
2024 Q2
3 quarters
BBIO icon
2
BridgeBio Pharma
BBIO
$15.2B
$6.36M 7.56%
183,922
-78,219
-30% -$2.64M
2023 Q4
5 quarters
VRNA
3
DELISTED
Verona Pharma
VRNA
$6.15M 7.31%
+96,821
New +$5.79M
2025 Q1
0 quarters
LEGN icon
4
Legend Biotech
LEGN
$3.12B
$5.44M 6.48%
160,442
+90,848
+131% +$3.26M
2024 Q2
3 quarters
PFE icon
5
Pfizer
PFE
$157B
$4.97M 5.91%
+196,164
New +$5.13M
2025 Q1
0 quarters
URGN icon
6
UroGen Pharma
URGN
$1.56B
$4.69M 5.57%
423,632
+122,426
+41% +$1.31M
2024 Q4
1 quarter
COGT icon
7
Cogent Biosciences
COGT
$4.83B
$4.64M 5.52%
774,721
-136,144
-15% -$1.07M
2024 Q4
1 quarter
ORIC icon
8
Oric Pharmaceuticals
ORIC
$800M
$4.57M 5.44%
819,194
-761,551
-48% -$6.66M
2024 Q3
2 quarters
TVTX icon
9
Travere Therapeutics
TVTX
$4.64B
$4.26M 5.06%
+237,487
New +$4.82M
2025 Q1
0 quarters
TERN icon
10
DELISTED
Terns Pharmaceuticals
TERN
$3.75M 4.46%
1,357,153
-663,409
-33% -$2.71M
2024 Q2
3 quarters
CYTK icon
11
Cytokinetics
CYTK
$7.17B
$2.93M 3.49%
72,992
-56,397
-44% -$2.59M
2023 Q4
5 quarters
SVRA icon
12
Savara
SVRA
$1.15B
$2.68M 3.18%
966,203
+457,865
+90% +$1.26M
2023 Q4
5 quarters
SMMT icon
13
Summit Therapeutics
SMMT
$8.45B
$2.55M 3.03%
132,019
-32,545
-20% -$653K
2024 Q4
1 quarter
SWTX icon
14
DELISTED
SpringWorks Therapeutics
SWTX
$2.39M 2.85%
+54,216
New +$2.5M
2025 Q1
0 quarters
CAPR icon
15
Capricor Therapeutics
CAPR
$438M
$2.29M 2.72%
241,192
+185,963
+337% +$2.58M
2024 Q3
2 quarters
VSTM icon
16
Verastem
VSTM
$864M
$2.03M 2.41%
336,363
+126,474
+60% +$773K
2024 Q4
1 quarter
TARA icon
17
Protara Therapeutics
TARA
$148M
$1.53M 1.82%
360,000
– –
2024 Q4
1 quarter
CRNX icon
18
DELISTED
Crinetics Pharmaceuticals
CRNX
$1.46M 1.74%
+43,613
New +$1.63M
2025 Q1
0 quarters
SLNO icon
19
DELISTED
Soleno Therapeutics
SLNO
$1.38M 1.64%
+19,332
New +$941K
2025 Q1
0 quarters
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$9.22B
$1.26M 1.5%
3,815
+2,686
+238% +$883K
2024 Q4
1 quarter
MLTX icon
21
MoonLake Immunotherapeutics
MLTX
$939M
$1.26M 1.49%
+32,145
New +$1.39M
2025 Q1
0 quarters
TSHA icon
22
Taysha Gene Therapies
TSHA
$1.23B
$1.05M 1.25%
+755,599
New +$1.26M
2025 Q1
0 quarters
TECX icon
23
Tectonic Therapeutic
TECX
$411M
$899K 1.07%
+50,746
New +$1.65M
2025 Q1
0 quarters
ZBIO icon
24
Zenas BioPharma
ZBIO
$1.7B
$882K 1.05%
111,605
– –
2024 Q3
2 quarters
ETNB icon
25
DELISTED
89bio
ETNB
$794K 0.94%
109,156
-23,826
-18% -$208K
2023 Q4
5 quarters

Similar funds

Superstring Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Superstring Capital Management held 53 positions worth $84M, down 27% from $115M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Superstring Capital Management withdrew a net $23M in Q1 2025, closing 19 positions and reducing 9 holdings. Its most notable exit was NovoCure, an estimated $8.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Superstring Capital Management opened a new position in Verona Pharma worth $6.15M.

  • Superstring Capital Management's largest Q1 2025 buy was Verona Pharma: 96,821 shares worth $6.15M.
  • Superstring Capital Management added most to Legend Biotech in Q1 2025, an estimated $3.26M increase.
  • Superstring Capital Management's biggest Q1 2025 reduction was Oric Pharmaceuticals, cutting an estimated $6.66M.
  • Superstring Capital Management fully exited NovoCure in Q1 2025, selling an estimated $8.55M.
  • Superstring Capital Management's ten largest holdings make up 66% of its $84M portfolio in Q1 2025.
  • Superstring Capital Management opened 14 new positions and closed 19 in Q1 2025.
  • Superstring Capital Management's portfolio value fell 27% quarter-over-quarter to $84M.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.